Amina holds an MSc in Drug Discovery and Pharma Management from University College London, where her research explored the regulatory landscape for gene therapies and the market access challenges associated with high-cost treatments for rare diseases.

She brings experience across pharmaceutical and MedTech HTA, pricing and reimbursement, and healthcare funding and coding systems in a range of global markets, with expertise across oncology, rare diseases, neurology, and pain. Her background in management consulting has equipped her with a strategic, analytical, and client-focused approach, enabling her to deliver practical insights and value across a diverse range of engagements.

‍

“Innovation only makes a difference when patients can access it. I enjoy helping clients navigate the evidence, policy, and access landscapes that shape access to life-changing therapies worldwide.”